172 related articles for article (PubMed ID: 34052550)
1. Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
Ye Z; Wu L; Zhang X; Hu Y; Zheng L
J Pharm Biomed Anal; 2021 Aug; 202():114161. PubMed ID: 34052550
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
3. UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies.
Cui Y; Li Y; Fan L; An J; Wang X; Fu R; Dong Z
J Pharm Biomed Anal; 2021 Nov; 206():114360. PubMed ID: 34508926
[TBL] [Abstract][Full Text] [Related]
4. A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma.
Gu EM; Liu YN; Pan L; Hu Y; Ye X; Luo P
Front Pharmacol; 2022; 13():955263. PubMed ID: 36160432
[TBL] [Abstract][Full Text] [Related]
5. Development of a UPLC-MS/MS method for simultaneous therapeutic drug monitoring of anti-hepatocellular carcinoma drugs and analgesics in human plasma.
Lu S; Zhao M; Zhao L; Li G
Front Pharmacol; 2023; 14():1136735. PubMed ID: 37324468
[TBL] [Abstract][Full Text] [Related]
6. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring.
Llopis B; Robidou P; Tissot N; Pinna B; Gougis P; Aubart FC; Campedel L; Abbar B; Weil DR; Uzunov M; Gligorov J; Salem JE; Funck-Brentano C; Zahr N
J Pharm Biomed Anal; 2021 Apr; 197():113968. PubMed ID: 33618135
[TBL] [Abstract][Full Text] [Related]
8. A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study.
Cui Y; Li Y; Li X; Fan L; He X; Fu Y; Dong Z
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209080
[TBL] [Abstract][Full Text] [Related]
9. A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
Zanchetta M; Iacuzzi V; Posocco B; Bortolin G; Poetto AS; Orleni M; Canil G; Guardascione M; Foltran L; Fanotto V; Puglisi F; Gagno S; Toffoli G
PLoS One; 2021; 16(10):e0259137. PubMed ID: 34699578
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.
Li G; Zhao M; Zhao L
J Pharm Biomed Anal; 2022 Apr; 212():114517. PubMed ID: 35131665
[TBL] [Abstract][Full Text] [Related]
11. A Broad Range High-Throughput Assay for Lenvatinib Using Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry With Clinical Application in Patients With Hepatocellular Carcinoma.
Sueshige Y; Shiraiwa K; Honda K; Tanaka R; Saito T; Tokoro M; Iwao M; Endo M; Arakawa M; Tatsuta R; Seike M; Murakami K; Itoh H
Ther Drug Monit; 2021 Oct; 43(5):664-671. PubMed ID: 34521802
[TBL] [Abstract][Full Text] [Related]
12. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
14. A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis.
Mano Y; Kusano K
J Pharm Biomed Anal; 2015 Oct; 114():82-7. PubMed ID: 26026266
[TBL] [Abstract][Full Text] [Related]
15. Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
He X; Li Y; Ma Y; Fu Y; Xun X; Cui Y; Dong Z
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234746
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ding J; Chen X; Dai X; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():108-15. PubMed ID: 22503745
[TBL] [Abstract][Full Text] [Related]
17. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS.
Jiang W; Zhao T; Zhen X; Jin C; Li H; Ha J
Front Pharmacol; 2022; 13():920436. PubMed ID: 35800447
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats.
Cui Y; Li Y; Guo C; Li Y; Ma Y; Dong Z
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080187
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Allard M; Khoudour N; Rousseau B; Joly C; Costentin C; Blanchet B; Tournigand C; Hulin A
J Pharm Biomed Anal; 2017 Aug; 142():42-48. PubMed ID: 28494338
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
Pang YY; Tan YL; Ho HK
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
